The ChEMBL-og

    Drug modalities continue to evolve and the capture of data from recent literature ensures that ChEMBL remains up-to-date with recent developments. Drugs and clinical candidates in ChEMBL undergo enhanced curation , including annotation of their drug mechanisms (the therapeutic target with a role in disease efficacy and the action type of the drug against the entity, e.g. INHIBITOR). Classical small-molecule modulators typically bind to the active site of a target, leading to either a loss or, in some cases, an increase in protein function. More recently, emerging strategies such as Targeted Protein Degradation (TPD) have gained traction and instead remove (degrade) the target. The growing body of TPD data in ChEMBL will be discussed in this blog post.    Targeted Protein Degraders ( PROTACs ) from the ChEMBL database. To explore TPD data in ChEMBL, we’ve used a combination of TPD-relevant keywords and effector protein accessions (UniProt). If you’re interested in...

I am delighted to announce that registration is open for the 2nd ChEMBL User Group Meeting , which is dedicated to building and supporting the ChEMBL and SureChEMBL user communities. The last meeting took place in 2011, so it feels like it might be time for a second :-). The UGM will take place on 10-11 June here on the Wellcome Genome Campus, Hinxton, near Cambridge, UK. It is a two-day event, with participant numbers limited for Day 2. Day 1 (Hybrid, in-person recommended): Talks, discussions, and networking, followed by an evening reception with drinks. Lunch will be provided. Day 2 (In-person only): A chance to influence the future development of ChEMBL and SureChEMBL. Deeper community sessions together with the ChEMBL and SureChEMBL teams, discussion of collaboration opportunities. As a community event, we encourage poster and oral presentations from community members on any topic related to the use of ChEMBL or SureChEMBL. Please indicate when registering if you would like...

Over the years, ChEMBL has accepted 336 datasets deposited by the community. In fact, these data now comprise around 50% of the bioactivity data points. This is in addition to ChEMBL’s core data, bioactivity data extracted from the medicinal chemistry literature, and drug and clinical candidate data curated from regulatory authorities and clinical trials. However, ChEMBL - like many other open access databases - is currently facing a reduction in funding. While we remain committed to maintaining the core of ChEMBL’s literature-extracted bioactivity data as well as drug data annotations, these constraints mean that in the future we may not be able to accept data depositions unless they are accompanied by appropriate funding. This applies particularly to those that require extensive curation or substantial manual intervention (*). Any depositions that have been agreed or are already in progress will be handled as planned. Beyond this, we will continue to prioritise depositions that a...